Skip to main content
Top
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | NSCLC | Primary research

The structure of blood–tumor barrier and distribution of chemotherapeutic drugs in non-small cell lung cancer brain metastases

Authors: Ling-yun Ye, Li-xiang Sun, Xiu-hua Zhong, Xue-song Chen, Song Hu, Rong-rong Xu, Xiao-ning Zeng, Wei-ping Xie, Hui Kong

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Brain metastasis is an important cause of increased mortality in patients with non-small cell lung cancer (NSCLC). In brain metastasis, the blood–brain barrier (BBB) is frequently impaired, forming blood–tumor barrier (BTB). The efficacy of chemotherapy is usually very poor. However, the characteristics of BTB and the impacts of BTB on chemotherapeutic drug delivery remain unclear. The present study investigated the structure of BTB, as well as the distribution of routine clinical chemotherapeutic drugs in both brain and peripheral tumors.

Methods

Bioluminescent image was used to monitor the tumor load after intracranial injection of lung cancer Lewis cells in mice. The permeability of BBB and BTB was measured by fluorescent tracers of evans blue and fluorescein sodium. Transmission electron microscopy (TEM), immunohistochemistry and immunofluorescence were performed to analyze structural differences between BBB and BTB. The concentrations of chemotherapeutic drugs (gemcitabine, paclitaxel and pemetrexed) in tissues were assayed by liquid chromatography with tandem mass spectrometry (LC-MS/MS).

Results

Brain metastases exhibited increased BTB permeability compared with normal BBB detected by fluorescence tracers. TEM showed abnormal blood vessels, damaged endothelial cells, thick basement membranes, impaired intercellular endothelial tight junctions, as well as increased fenestrae and pinocytotic vesicles in metastatic lesions. Immunohistochemistry and immunofluorescence revealed that astrocytes were distributed surrounded the blood vessels both in normal brain and the tumor border, but no astrocytes were found in the inner metastatic lesions. By LC-MS/MS analysis, gemcitabine showed higher permeability in brain metastases.

Conclusions

Brain metastases of lung cancer disrupted the structure of BBB, and this disruption was heterogeneous. Chemotherapeutic drugs can cross the BTB of brain metastases of lung cancer but have difficulty crossing the normal BBB. Among the three commonly used chemotherapy drugs, gemcitabine has the highest distribution in brain metastases. The permeability of chemotherapeutic agents is related to their molecular weight and liposolubility.
Literature
1.
go back to reference Siegel R, et al. Cancer statistics, 2011. Cancer J Clin. 2011;61(4):212–36.CrossRef Siegel R, et al. Cancer statistics, 2011. Cancer J Clin. 2011;61(4):212–36.CrossRef
2.
go back to reference Li G. Meta-analysis of GSTM1 null genotype and lung cancer risk in Asians. Med Sci Monit. 2014;20:1239–45.CrossRef Li G. Meta-analysis of GSTM1 null genotype and lung cancer risk in Asians. Med Sci Monit. 2014;20:1239–45.CrossRef
3.
go back to reference Eichler AF, et al. The biology of brain metastases—translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344–56.CrossRef Eichler AF, et al. The biology of brain metastases—translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344–56.CrossRef
4.
go back to reference Sørensen JB, et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6(9):1474–80.CrossRef Sørensen JB, et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6(9):1474–80.CrossRef
5.
go back to reference Lagerwaard F, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43(4):795–803.CrossRef Lagerwaard F, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43(4):795–803.CrossRef
6.
go back to reference Pfannschmidt J, Dienemann H. Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer. 2010;69(3):251–8.CrossRef Pfannschmidt J, Dienemann H. Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer. 2010;69(3):251–8.CrossRef
7.
go back to reference Villaruz LC, et al. Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep. 2012;14(4):333–41.CrossRef Villaruz LC, et al. Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep. 2012;14(4):333–41.CrossRef
9.
go back to reference Steeg PS, et al. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11(5):352–63.CrossRef Steeg PS, et al. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11(5):352–63.CrossRef
10.
go back to reference Oberhoff C, et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Oncol Res Treat. 2001;24(3):256–60.CrossRef Oberhoff C, et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Oncol Res Treat. 2001;24(3):256–60.CrossRef
11.
go back to reference Krop IE, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113–9.CrossRef Krop IE, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113–9.CrossRef
12.
go back to reference Lin NU, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.CrossRef Lin NU, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.CrossRef
13.
go back to reference Deeken JF, Löscher W. The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663–74.CrossRef Deeken JF, Löscher W. The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663–74.CrossRef
14.
go back to reference Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood–brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res. 2007;24(9):1745–58.CrossRef Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood–brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res. 2007;24(9):1745–58.CrossRef
15.
go back to reference Gerstner ER, Fine RL. Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25(16):2306–12.CrossRef Gerstner ER, Fine RL. Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25(16):2306–12.CrossRef
16.
go back to reference de Vries NA, et al. Blood–brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother. 2006;6(8):1199–209.CrossRef de Vries NA, et al. Blood–brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother. 2006;6(8):1199–209.CrossRef
17.
go back to reference Donelli MG, et al. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol. 1992;30(4):251–60.CrossRef Donelli MG, et al. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol. 1992;30(4):251–60.CrossRef
18.
go back to reference Whitsett TG, et al. Molecular determinants of lung cancer metastasis to the central nervous system. Transl Lung Cancer Res. 2013;2(4):273–83.PubMedPubMedCentral Whitsett TG, et al. Molecular determinants of lung cancer metastasis to the central nervous system. Transl Lung Cancer Res. 2013;2(4):273–83.PubMedPubMedCentral
19.
go back to reference Pérez-Larraya JG, Hildebrand J. Brain metastases. Handb Clin Neurol. 2014;121:1143–57.CrossRef Pérez-Larraya JG, Hildebrand J. Brain metastases. Handb Clin Neurol. 2014;121:1143–57.CrossRef
20.
go back to reference Dubois LG, et al. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci. 2014;8:418.CrossRef Dubois LG, et al. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci. 2014;8:418.CrossRef
21.
22.
go back to reference Fortin D. The blood–brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets. 2012;12(3):247–59.CrossRef Fortin D. The blood–brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets. 2012;12(3):247–59.CrossRef
23.
go back to reference Fu Y, et al. Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer. J Chemother. 2016;28(3):218–24.CrossRef Fu Y, et al. Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer. J Chemother. 2016;28(3):218–24.CrossRef
24.
go back to reference Zhang RD, et al. Differential permeability of the blood–brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol. 1992;141(5):1115–24.PubMedPubMedCentral Zhang RD, et al. Differential permeability of the blood–brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol. 1992;141(5):1115–24.PubMedPubMedCentral
25.
go back to reference Miles FL, et al. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis. 2007;25(4):305–24.CrossRef Miles FL, et al. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis. 2007;25(4):305–24.CrossRef
26.
go back to reference Zhao L-n, et al. Vascular endothelial growth factor increases permeability of the blood–tumor barrier via caveolae-mediated transcellular pathway. J Mol Neurosci. 2010;44(2):122–9.CrossRef Zhao L-n, et al. Vascular endothelial growth factor increases permeability of the blood–tumor barrier via caveolae-mediated transcellular pathway. J Mol Neurosci. 2010;44(2):122–9.CrossRef
27.
go back to reference Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2009;119(1):7–35.CrossRef Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2009;119(1):7–35.CrossRef
28.
go back to reference Ahluwalia MS, et al. Brain metastasis and treatment. F1000Prime Rep. 2014;6:114.CrossRef Ahluwalia MS, et al. Brain metastasis and treatment. F1000Prime Rep. 2014;6:114.CrossRef
29.
go back to reference Valiente M, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002–16.CrossRef Valiente M, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002–16.CrossRef
30.
go back to reference Marike L, et al. Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol. 2018;14(8):482–95.CrossRef Marike L, et al. Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol. 2018;14(8):482–95.CrossRef
31.
go back to reference Lo Cicero A, et al. Oligodendroglioma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes. Int J Oncol. 2011;39(6):1353–7.PubMed Lo Cicero A, et al. Oligodendroglioma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes. Int J Oncol. 2011;39(6):1353–7.PubMed
32.
go back to reference Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?—a review. Transl Lung Cancer Res. 2016;5(1):26–38.PubMedPubMedCentral Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?—a review. Transl Lung Cancer Res. 2016;5(1):26–38.PubMedPubMedCentral
33.
go back to reference Gimsa U, et al. Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm. 2013;2013:1–11.CrossRef Gimsa U, et al. Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm. 2013;2013:1–11.CrossRef
34.
go back to reference Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem. 2009;17(8):2950–62.CrossRef Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem. 2009;17(8):2950–62.CrossRef
35.
go back to reference Fellner S, et al. Transport of paclitaxel (Taxol) across the blood–brain barrier in vitro and in vivo. J Clin Invest. 2002;110(9):1309–18.CrossRef Fellner S, et al. Transport of paclitaxel (Taxol) across the blood–brain barrier in vitro and in vivo. J Clin Invest. 2002;110(9):1309–18.CrossRef
Metadata
Title
The structure of blood–tumor barrier and distribution of chemotherapeutic drugs in non-small cell lung cancer brain metastases
Authors
Ling-yun Ye
Li-xiang Sun
Xiu-hua Zhong
Xue-song Chen
Song Hu
Rong-rong Xu
Xiao-ning Zeng
Wei-ping Xie
Hui Kong
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02263-6

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine